|Chemical and physical data|
|Molar mass||198.26 g/mol|
|3D model (JSmol)|
Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.
- "Lanicemine". AdisInsight. Retrieved 18 June 2017.
- Machado-Vieira, R; Henter, ID; Zarate CA, Jr (May 2017). "New targets for rapid antidepressant action.". Progress in neurobiology. 152: 21–37. PMC . PMID 26724279. doi:10.1016/j.pneurobio.2015.12.001.
- Zarate, C. A.; Mathews, D.; Ibrahim, L.; Chaves, J. F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N. E.; Smith, M. A.; Luckenbaugh, D. A. (2012). "A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression". Biological Psychiatry. 74 (4): 257–264. PMC . PMID 23206319. doi:10.1016/j.biopsych.2012.10.019.
- Flowers, Sophie. "Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company". Retrieved 6 February 2014.